Company ProfilePremium

Fresenius Kabi AG

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Fresenius Kabi AG - Healthcare showcase

Year Founded & Workforce

1999

316,078 Employees

Industry

Healthcare

Services

Medical Food
F

Fresenius Kabi AG Employee Contacts

188 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Fresenius Kabi AG Overview

Company Headquarters: Hessen, Germany

Founded: 1999

Workforce: ~316,078

Company Working: Fresenius Kabi AG is a pharmaceutical company with a wide portfolio that includes intravenously administered drugs, infusion therapy, clinical nutrition, medical devices, and transfusion technology. Its product portfolio also comprises a comprehensive range of infusion therapies, I.V. generic drugs, clinical nutrition products, and the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi provides products for gathering and managing blood components and for the therapeutic treatment of patient blood by apheresis systems. They have a production network that spans around 70 production sites, including compounding centers in Europe, North America, Latin America, Asia-Pacific, and Africa.

Strategy

Fresenius Kabi AG is focused on building a portfolio of medical foods to address the growing demand from hospitals and outpatient facilities and promote safety and convenience by using its innovative freeflex bag and port design. Its strategy is to use science-based innovation to deliver better medical food outcomes to customers. It aims to lead the growing healthcare sector by winning new patents and developing high-quality technologies.

Company Snapshot

$39,653.1M

Revenue

316,078

Employees

1999

Founded

Hessen, Germany

Headquarters

SWOT Analysis

Strengths

  • Strong history of innovation
  • Strong distribution channel
  • Strong manufacturing facility

Weaknesses

  • Need more production and manufacturing power
  • Performance is dependent on prevailing exchange rates

Opportunities

  • Increasing research & development activity

Threats

  • Strict government regulations
  • Political risks

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
October 2019ExpansionFresenius Kabi AG (Germany) has expanded of its plant in Aquiraz, Brazil to increase the facility’s capacity for parenteral nutrition production by around 30 percent

Product Offering

  • Fresenius Kabi AG
    • Medical Food

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 39,653.1 Mn in 2019 to USD 42,487.6 Mn in 2021.
Fresenius Kabi AG — By Business Segment
Series (USD Mn)201920202021
Sales39,653.144,556.942,487.6
R&D Expenditure758.1918.7926.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.